Sign in

    QIAGEN (QGEN)

    Q1 2024 Earnings Summary

    Reported on Feb 15, 2025 (After Market Close)
    Pre-Earnings Price$43.54Last close (Apr 30, 2024)
    Post-Earnings Price$43.37Open (May 1, 2024)
    Price Change
    $-0.17(-0.39%)

    What went well

    • QIAGEN's key products are showing strong double-digit sales growth, with QuantiFERON achieving 11% CER sales growth and QIAstat diagnostic sales up 21% CER in the first quarter of 2024, indicating robust demand and solidifying market position.
    • Management reaffirms confidence in achieving the full-year 2024 outlook, expecting net sales of at least $2 billion at CER and adjusted EPS of at least $2.10 at CER, demonstrating strong earnings potential and commitment to deliver on guidance despite macroeconomic challenges.
    • QIAGEN is committed to improving profitability, aiming for an adjusted operating income margin of at least 28% for 2024, up from 25.7% in Q1 2024, reflecting operational efficiency gains and strategic investments that enhance shareholder value.

    What went wrong

    • QIAGEN does not expect the Chinese market to bounce back anytime soon, at least not before 2025, which could negatively impact their sales in the Asia-Pacific region.
    • There is softness in the life science market, with customers showing cautiousness in capital spending, especially on capital expenses, which may affect QIAGEN's instrument sales and overall growth in the life science segment.
    • The Sample Technologies business is expected to grow only at a low single-digit rate for 2024, and continued market softness could pose risks to achieving even this modest growth target.

    Q&A Summary

    1. China Sales
      Q: What's the outlook for China sales this year?
      A: We don't expect the Chinese market to bounce back before the end of 2024 or 2025. The market is in a transition phase post-COVID, affecting both life science and clinical diagnostics. Our exposure is limited at 6% of revenues , and we're investing in local R&D and manufacturing, plus a dedicated brand for Chinese customers.

    2. NeuMoDx Decision
      Q: Any updates on the NeuMoDx business review?
      A: We will make a definitive decision by June 17. We're considering several scenarios, including finding partners or shutting down activities; both options are accretive to our P&L, gross margin, EBIT margin, and EPS.

    3. QuantiFERON Growth Outlook
      Q: How is QuantiFERON expected to perform this year?
      A: We're on track to achieve our target of over $450 million. The Oman collaboration is included in our guidance. Growth traditionally accelerates in Q3 and Q4 due to initiatives like back-to-school programs in the U.S..

    4. Margin Expectations
      Q: Can you discuss margin expectations for this year?
      A: We expect operating income adjusted to reach the 27% range in Q2 and at least 28% for the full year. R&D investment remains around 10% of sales. There's leverage opportunity in SG&A, and we see margin improvement options not only for 2024 but beyond.

    5. LDT Regulation Impact
      Q: What's your view on the FDA's LDT ruling?
      A: It's premature to comment extensively as the text is 532 pages long and was just released. Our exposure is very limited, not significant at this moment. We believe it might reinforce our position as a supplier of quality components to labs developing LDTs.

    6. Capital Allocation Priorities
      Q: What are your capital allocation priorities?
      A: First, we prioritize profitable organic investment in R&D, maintaining R&D investment slightly above 10% of sales. Second, we're actively looking at accretive and synergistic bolt-on acquisitions. Third, we consider returning value to shareholders through actions like share buybacks.

    7. Market Conditions and Instrument Sales
      Q: How are market conditions affecting instrument sales?
      A: There's cautiousness in capital spending due to many countries heading into elections. The instrumentation business is challenging, especially for instruments over $100,000. However, products like QIAcuity and QIAstat, priced around $30,000–$40,000, are performing well.

    8. PCR Business Outlook
      Q: What's the outlook for your PCR business?
      A: We expect the PCR business to improve sequentially throughout the year. We have a significant installed base driving this assumption. Our focus is on the digital PCR portfolio, where we aim to take the #1 position in the market.

    9. Genomics Business Performance
      Q: Can you discuss the genomics business performance?
      A: The Q1 decline was mainly due to timing of revenue recognition for a large contract. This doesn't affect our goal for double-digit growth for the rest of the year.

    10. Investor Day Goals
      Q: What are your goals for the upcoming Investor Day?
      A: We'll outline our top-line and bottom-line ambitions for the next four years. We'll show significant growth drivers in our portfolio and how we'll improve profitability through efficiency measures.

    Analyst Coverage

    Research analysts covering QIAGEN.

    Related Publications